



Immunohistochemical detection of GFAP and TGF β 1 in C57Bl6 mice during acute vesicular stomatitis virus encephalitis

Detecção imunoistoquímica de TGF-BETA e GFAP em camundongos C57Bl6 com encefalite aguda induzida pelo vírus da estomatite vesicular

Gisele Fabrino Machado¹, Paulo Cesar Maiorka², Cinthia Graziela Candioto¹, Luciana Mari Ushiro Ieiri¹ & Antonio Carlos Alessi³

ABSTRACT

Activation of astrocytes or astrogliosis is a prominent component of the inflammatory response and an indicator of injury in the brain. These astrocytes produce a large array of inflammatory mediators, growth and neuroprotective factors. This study was an investigation from astrocyte (GFAP) response and TGF- β 1 involvement during VSV acute encephalitis using immunohistochemistry to verify relation between astrocytes and TGF- β 1. Animals developed symptoms around 6th day after VSV inoculation. Viral proteins were mainly detected at olfactory bulb, ventricular cell layer and disseminated to hippocampus, mesencephalon and diencephalon areas and brain stem. Also at 6th day post inoculation GFAP and TGF- β 1 staining was observed in good association with virus-detected areas of brain. However, in mice with severe symptoms we observed reduction in the intensity of GFAP labeling at the same areas where TGF- β 1 upregulation was observed. These areas show correlation with areas of necrosis and where are astrocytes with degenerative aspect. We observed TGF- β 1 staining in damaged astrocytes, suggesting an effort of those cells in controlling inflammation in acute phase of VSV encephalitis.

Key words: astrocytes, gliosis, TGF- β , vesicular stomatitis virus.

RESUMO

Ativação de astrócitos ou astrogliose é um componente evidente da resposta inflamatória e um indicador de injúria no sistema nervoso. Estes astrócitos produzem uma grande combinação de mediadores inflamatórios, fatores de crescimento e neuroprotetores. Este trabalho investiga a resposta de astrócitos (GFAP) e a participação de TGF- β 1 durante a fase aguda da encefalite por VSV usando imunoistoquímica para verificar a relação entre astrócitos e TGF- β 1. Os camundongos desenvolveram sintomas cerca de 6 dias após a inoculação (pi) do VSV. As proteínas virais foram detectadas principalmente no bulbo olfatório, células ventriculares e disseminadas em áreas do hipocampo, mesencéfalo e diencefalo. Também no sexto dia pi, a marcação para GFAP e TGF- β 1 foi observada associada com áreas onde o vírus foi detectado. Entretanto, em camundongos com sintomas severos, nós observamos áreas onde a marcação para TGF- β 1 foi mais intensa. Estas áreas apresentaram correlação com áreas de necrose, onde astrócitos degenerados foram observados. A marcação para TGF- β 1 em astrócitos lesados, sugeriu um esforço destas células em controlar a inflamação na fase aguda da encefalite por VEV.

Descritores: astrócitos, Gliose, TGF- β 1, vesicular estomatite vírus.

INTRODUCTION

Activation of astrocytes or astrogliosis is a prominent component of the inflammatory response and an indicator of injury in the brain. These astrocytes produce a large array of inflammatory mediators, growth and neuroprotective factors [29,30]. Communication between astrocytes and astrocytes or other cells in CNS occurs by gap junctions and it could result in a favorable metabolic co-operation [2]. Whereas some of these effects are clearly beneficial, astrocyte communication could mediate additional death of the adjacent cells by the bystander effect [2].

Mice with moderate or low levels of TGF- β 1 expression had a less pronounced astrogliosis, whereas GFAP expression was consistently increased [28]. Indeed, TGF- β 1 directly increases GFAP transcription in cultured astrocytes [22]. Studies on cultured neurons show a protective effect of TGF-1 against various toxins and injurious agents. Little is known about TGF- β 1 rules during acute phase of CNS injuries in an animal model [reviewed in 25].

Mice experimental infection of vesicular stomatitis virus by the intranasal route results in spread by retrograde transport in neurons and ventricular surfaces [12,20]. Current data suggests that acute encephalitis induces apoptosis, tissue injury, and mortality in VSV-infected mice [24].

The aim of the present study was to investigate the possible correlation between astrocytes (GFAP) and TGF β 1 during acute phase of vesicular stomatitis virus encephalitis comparing the localization of both proteins in encephalon of symptomatic and asymptomatic mice.

MATERIALS AND METHODS

Virus

The sample of vesicular stomatitis virus, strain Indiana type II was maintained at -80°C in BHK. Mouse brain suspension used for inoculation was obtained from intracerebral inoculation of mice as previously described [20]. The VSV titration was determined as infecting dose per tissue culture (TCID₅₀/0.1 ml) expressed in decimal logarithms was 10⁵ virus/0,1ml.

Experimental infection of mice

Thirty male C57Bl6 mice, 5 to 7 weeks old (CEMIB-UNICAMP-SP-Brazil), were used for viral inoculation. Mice were mildly anesthetized in a closed

container with ether followed by intranasal inoculation with VSV suspension (10⁵ virus/0.1ml) in a total volume of 0.03ml administered equally between each nostril according to [11]. Five mice got sterile PBS into the nostril were used as control (Group 1). Animals were housed with food and water *ad libitum* and were randomly sacrificed for histological and immunohistochemical analysis at day 6, symptomatic mice comprised Group 2, and asymptomatic mice, Group 3. Each group was composed by at least 6 mice. All the protocols were approved and experiments were carried out in agreement with UNESP- Animal Ethic in Animal Experimentation Committee for animal care.

Histological and Immunohistochemical analysis

Mice were anesthetized with ether and sacrificed with intraperitoneal lethal dose of 5mg of pentobarbital sodium (Nembutal[®] - Abbott Laboratories) in normal saline solution. Each mouse was perfused transcardially with 30-40ml of phosphate-buffered saline (PBS pH 7.4). After perfusion whole brains were removed and fixed during 8 hours in freshly prepared 4% buffered paraformaldehyde (pH 7.4) and embedded in paraffin according to standard procedures. Selected areas were based on viral dissemination route described by [12,20].

Five-micrometer brain longitudinal sections were stained with hematoxylin and eosin in order to detect inflammatory, degenerative or reactive features of neurons. For immunohistochemistry, endogenous peroxidase activity was blocked by incubating sections in 1% H₂O₂. Sections were treated with Tripsin 1% at 37°C before blocking of nonspecific binding with powdered skimmed milk (3% in phosphate-buffered saline) for 30 minutes. Incubation with primary antibodies was performed overnight at 4°C. For demonstration of astrocytes morphology polyclonal anti-GFAP was used (1:400, Dako²) and for characterization of TGF- β 1 distribution we used anti-TGF- β 1 (Santa Cruz³, SC-146). Biotinylated anti-rabbit (1:100, Dako²) and anti-goat (Santa-Cruz, 1:100) was applied as secondary antibodies and avidin-biotin-peroxidase complex (ABC kit, Vector Laboratories, USA) served as the third reagent. Positive antigen-antibody reaction was visualized by incubation with 3,3-diaminobenzidine-tetrahydrochloride-(DAB)-H₂O₂ followed by counterstain with Mayer hematoxylin. Negative control sections were incubated in the absence of the primary antibody.

RESULTS

Clinical signs

Six inoculated mice showed signs of disease at 6th day post inoculation (pi). Typical clinical signs included ruffled fur, conjunctivitis, reduced mobility and progressive posterior paralysis. To minimize suffering to the animals they were sacrificed at start of the paralysis symptoms.

Histopathology

Brains observed at 6th day post inoculation showed intense inflammation in the olfactory bulb. Leptomeningitis, which the intensity varied from mild to intense, was observed at olfactory bulb and extended to encephalic ventral surface. Most affected mice showed necrosis at olfactory bulb and also ventriculitis at laterals, third and fourth ventricles affecting subependymal layer (Figure 1A). Perivascular infiltrates and necrosis was also observed at thalamus, hypothalamus and brain stem. Inflammatory infiltrates were composed by neutrophils and lymphocytes.

Immunohistochemistry for viral antigen

Six days after nasal instillation, in symptomatic mice (Group 3), VSV proteins were detected at olfactory bulb, ependymal and subependymal layers, hippocampal, hypothalamic and thalamic areas, some nucleus at mesencephalon and brain stem. Cerebellum and cortical areas were less affected (Figure 1D).

Immunohistochemistry for GFAP

Astrocytes positive for GFAP were easily identified in animals of all groups (Table 1). Reactive astrocytes were characterized mainly for having large and clear nucleus, clumped chromatin located peripherally, and large nucleoli. The cytoplasm was evident and the thick processes were intensively stained. Cells with those characteristics were observed mainly in the glomerular and mitral cell layers of olfactory bulb, even in asymptomatic mouse sacrificed at day 6-post inoculation. Mice presenting symptoms sacrificed at day 6th showed astrogliosis in other encephalic areas as glia limitans externa, glia limitans interna, hippocampus, diencephalon and mesencephalon.

Strong to intense GFAP reactivity was characteristic on symptomatic mouse

(Table 1), apart from reduction in the intensity of the reaction in some areas of the encephalon that corresponds to necrotic areas of olfactory bulb and around ventricular areas. GFAP-positive cells, with large swollen nuclei, evident nucleoli and processes with a fragmented feature were observed in areas where inflammation was intense and necrosis could also be observed (Figure 1C and F). Surrounding necrotic tissue there was a transitional area where astrocytes showed less marked degenerative morphological aspects, i.e., the processes were short, thick and showed only a mild fragmentation.

Immunohistochemistry for TGF-β

TGF β1 immunoreactivity was observed at leptomeninges, at ependymal and subependymal cells and choroid plexus in control group (Group 1). Six days post VSV inoculation TGF-β upregulation was observed in encephalon associated to inflammation and VSV dissemination. Immunostaining was positive in neurons and astrocytes at olfactory bulb, in cells at subependymal area, in neurons and astrocytes of hippocampus and brain stem. Leptomeninges and choroid plexus epithelium showed positive staining, as some inflammatory cell at subpial and perivascular space. At olfactory bulb (Figure 1E) and periventricular ependymal and subependymal layer (Figure 1B) some structures similar to astrocytes processes also were marked. Positive extra cellular diffuse staining was also observed.

Table 1. General immunohistochemical staining patterns distribution for GFAP and TGF-β on brain of mice inoculated and sacrificed at 6 days post inoculation and controls.

Immunoreactivity	GFAP			TGF-β		
	G1 (n=4)	G2 (n=6)	G2 (n=9)	G1 (n=4)	G2 (n=6)	G2 (n=9)
Cortex	+	++	+	-	+++	-
Olfactory bulb	++	++	++	-	++++	+++
Ependymal and Subependymal layer	-	++	-	-	+++	-
Hippocampus	++	++++	++	-	+++	-
Diencephalon	++	++++	++	-	++	-
Mesencephalon	++	+++	++	+	+++	+
Brain Stem	++	+++	++	-	+++	-

(-) no staining; (+) weak staining; (+ +) moderate staining; (+ + +) strong staining; (+ + + +) intense staining. Group 1: Control; Group 2 : with symptoms at 6th day; Group 3: without symptoms at 6th day.




Figure 1. **A, B and C** - Serial sections of an infected brain removed at day six. **A** - Cells at subependymal layer showing signs of cell death (HE, bar = 25 μ m). **B** - TGF- β immunohistochemistry at subependymal layer of lateral ventricle (bar = 25 μ m). **C** - GFAP staining. Note attenuation of GFAP positivity inside square demarcated area (bar = 50 μ m). **D** - Distribution of VSV antigen in sagittal section of brain 6 days post inoculation. (OB) Olfactory bulb; (T) thalamus; (H) hippocampus formation; (Hy) hypothalamus; (M) mesencephalon; (Cb) cerebellum; (Br) brainstem (bar = 1mm). **E and F** - Serial sections of olfactory bulb. **E** - TGF- β intense staining at astrocytes (arrows) (bar = 25 μ m). **F** - Decreasing in GFAP detection. Only few structures are marked (arrows) (bar = 25 μ m).

DISCUSSION

Similar to the rabies virus, VSV presents neurotropism and the neuronal infection results in cell death. Acute CNS major lesion in VSV infection includes leptomeningitis and ventriculitis, followed by neuronal damage and a parallel glial activation. Viral migration in the course of infection occurs via olfactory tracts

and ventricles surface, involving hippocampus, diencephalon, mesencephalon, and brain stem [12, 20].

In mice sacrificed on day 6 without symptoms, the tissue injury was less intense and mainly limited to the olfactory bulb, where GFAP-positive astrocytes with activated morphology were observed. In those mice viral proteins were detected essentially in olfac-

tory bulb. In symptomatic mice at 6th day after virus inoculation reactive astrocytes were detected in the olfactory bulb and other areas such as hippocampus, mesencephalic and diencephalic areas and brain stem, thus confirming the observations of de [5,20,26], which described rapid response to VSV infection, both from astrocytes and also microglia activation. Areas where the down regulation of GFAP labeling was detected corresponded to sites where there was tissue necrosis, intense viral and TGFβ1 detection.

Astrocytes are important cells contributing to immune response, and also for healing and/or regeneration of nervous tissue. Down regulation of GFAP associated with morphological changes are a strong indicative of astrocyte degeneration. Morphological changes observed in nervous tissue, including those observed in astrocytes at 6th day pi may be caused by virus multiplication and beginning of cell death triggered by apoptosis [24]. However, neuron and glial cells are very likely to suffer injury secondary to the inflammatory process, as a bystander effect. Astrocyte degenerative changes might be associated with functional changes, which might contribute to the aggravation of CNS lesions [4, 21,23].

TGF-β1 has been found in glial cells, Schwann cells and in certain populations of neurons [9]. Comparing with control (Group 1), all groups had stronger staining, specially those mice with symptoms of Group 3. We observed neuronal cells stained positively for TGF-β1 at brain stem nucleus at day 6 pi. TGF-β1 expression in neurons is related with neurodegeneration [13]. So, in VSV model, TGF-β1 expression in neurons seems to be related to a response to viral neurotropism.

At olfactory bulb and ependymal and subependymal layers, crucial areas for virus dissemination, structures very similar to astrocytes processes presented TGF-β1 positivity (Figure 1E and F). On sequential sections, GFAP detection was almost inexpressive and suggested astrocyte damage. TGF-β1 has been found mainly in glial cells and is detected in low quantities at mature CNS. After different injuries TGF-β1 is synthesized by microglia and, at low levels, by astrocytes [1, 8,19]. In particular, astrocytic expression of TGF-β is a powerful suppressor of microglial cells [10,14,15,18].

Comparing both protein expressions on day six-post inoculation we noticed a commitment of astrocytes in synthesizes TGF-β1 during acute VSV infection. As general rule, reports with reference to TGFβ1 suggest the importance of this cytokine in chronic phase of diseases as modulator molecule witch interfere in cellular differentiation, extracellular matrix production and immunological response [3,7,16,17,27]. Recent research shows the importance of TGF-β1 and its signaling pathways as putative modulator of astrocyte biology and its implication as a possible novel mediator of cellular interactions in the CNS [6,25]. We observed TGFβ1 staining in damaged astrocytes, suggesting an effort of those cells in controlling inflammation in acute phase of VSV model of viral encephalitis.

Acknowledgements. We thanks financial support provided by FAPESP and FUNDUNESP.

NOTAS INFORMATIVAS

¹Abbot Laboratories - Abbott Park, Illinois, USA.

²Dako Cytomation - Carpinteria, Califórnia, USA.

³Santa Cruz Biotechnology – Santa Cruz, Califórnia, USA.

REFERENCES

- 1 **Acarin L., González B. & Castellano B. 2000.** Neuronal, astroglial and microglial cytokine expression after an excitotoxic lesion in the immature rat brain. *European Journal of Neuroscience*. 12: 3505-3520.
- 2 **Andrade-Rozental A.F., Rozental R., Hopperstad M.G., Wu J.K., Vrionis F.D. & Spray D.C. 2000.** Gap junctions: the “kiss of death” and the “kiss of life”. *Brain Research Reviews*. 32: 308-315.
- 3 **Araria-Goumidi L., Lambert J.C., Mann D.M., Lendon C., Frigard B., Iwatsubo T., Amouyel P. & Chartier-Harlin M.C. 2002.** Association study of three polymorphisms of TGF-beta1 gene with Alzheimer’s disease. *Neurology Neurosurgery & Psychiatry*. 73: 62-64.
- 4 **Aschner M. 1998.** Astrocytes as mediators of immune and inflammatory responses in the CNS. *Neurotoxicology*. 19: 269-282.
- 5 **Bi Z., Barna M., Komatsu T. & Reiss C.S. 1995.** Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. *Journal of Virology*. 69: 6466-6472.
- 6 **Carvalho A. G. F., Oliveira Souza V. & Romão L. 2005.** Emerging roles for TGF-beta1 in nervous system development. *International Journal of Developmental Neuroscience*. 23: 413-424.
- 7 **Cunningham C., Boche D. & Perry V.H. 2002.** Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. *Neuropathology and Applied Neurobiology*. 28: 107-119.

- 8 **De Groot C.J., Montagne L., Barten A.D., Sminia P. & Van Der Valk P. 1999.** Expression of transforming growth factor (TGF)-beta, -beta2, and beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocytes cultures. *Journal of Neuropathology and Experimental Neurology*. 58: 174-187.
- 9 **Flanders K.C., Ren R.F. & Lippa C.F. 1998.** Transforming growth factor-s in neurodegenerative disease. *Progress in Neurobiology*. 54: 71-85.
- 10 **Hu S., Chão C.C., Ehrlich L.C., Sheng W.S., Sutton R.L., Rockswold G.L. & Peterson P.K. 1999.** Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. *Journal of Leukocyte Biology*. 65: 815-821.
- 11 **Huneycutt B.S., Bi Z., Aoki C.J. & Reiss C.S. 1993.** Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. *Journal of Virology*. 67: 6698-6706.
- 12 **Huneycutt B.S., Plakohov I.V., Shusterman Z., Bartido S.M., Huang A., Reiss C.S. & Aoki C. 1994.** Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. *Brain Research*. 635: 81-95.
- 13 **Ilzecka J., Stelmasiak Z. & Dobosz B. 2002.** Transforming Growth Factor-Beta 1 (TGF- β 1) in Patients with Amyotrophic Lateral Sclerosis. *Cytokine*. 20: 239-243.
- 14 **Jones L.L., Kreutzberg G.W. & Raivich G. 1998.** Transforming growth factor beta's 1, 2 and 3 inhibit proliferation of ramified microglia on an astrocyte monolayer. *Brain Research*. 795: 301-306.
- 15 **Kim W.K., Hwang S.Y., Oh E.S., Piao H.Z., Kim K.W. & Ham I.O. 2004.** TGF-beta1 represses activation and resultant death of microglia via inhibition of phosphatidylinositol 3-kinase activity. *Journal of Immunology*. 172: 7015-7023.
- 16 **King V.R., Philips J.B., Brown R.A. & Priestley J.V. 2004.** The effects of treatment with antibodies to transforming growth factor beta1 and beta2 following spinal cord damage in the adult rat. *Neuroscience*. 126: 173-183.
- 17 **Lagord C., Berry M. & Logan A. 2002.** Expression of TGFbeta2 but not TGFbeta1 correlates with the deposition of scar tissue in the lesioned spinal cord. *Molecular and Cellular Neuroscience*. 20: 69-92.
- 18 **Ledeboer A., Breve J.J., Poole S., Tilders F.J. & Van Dam A.M. 2000.** Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. *Glia*. 30: 134-142.
- 19 **Lehrmann E., Kiefer R., Christensen T., Toyka K.V., Zimmer J., Diemer N.H., Hartung H-P. & Finsen B. 1998.** Microglia and macrophages are major sources of locally produced transforming growth factor- β 1 after transient middle cerebral artery occlusion in rats. *Glia*. 24: 437-448.
- 20 **Machado G.F., Chimelli L.M.C. & Figueiredo F.C. 2003.** Vesicular stomatitis virus (Indiana 2 sorotype) as experimental model to study acute encephalitis – Morphological features. (Portuguese). *Semina: Ciências Biológicas e da Saúde*. 24: 11-20.
- 21 **Mucke L. & Eddleston M. 1993.** Astrocytes in infectious and immune-mediated diseases of the central nervous system. *FASEB Journal*. 7: 1226-1232.
- 22 **Reilly J.F., Maher P.A. & Kumari V.G. 1998.** Regulation of astrocyte GFAP expression by TGF-beta1 and FGF-2. *Glia*. 22: 202-210.
- 23 **Sun N., Grzybicki D., Castro R.F., Murphy S. & Perlman S. 1995.** Activation of astrocytes in the spinal cord of mice chronically infected with a neurotropic coronavirus. *Virology*. 213: 482-493.
- 24 **Sur J.H., Allende R. & Doster A.R. 2003.** Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis. *Veterinary Pathology*. 40: 512-520.
- 25 **Unsicker K & Kriegelstein K. 2002.** TGF-betas and their roles in the regulation of neuron survival. *Advances in Experimental Medicine and Biology*. 513: 353-374.
- 26 **Vasconcelos R., Jardim L., Machado G.F. & Alessi A. C. 2004.** Morphologic variation of microglia in the experimental encephalitis for the vesicular stomatitis virus in mice. *Ars Veterinária*. 20: 228-232.
- 27 **Wahl S.M. 1994.** Transforming growth factor beta: the good, the bad, and the ugly. *Journal of Experimental Medicine*. 180: 1587-1590.
- 28 **Wyss-Coray T. 2004.** Transforming growth factor-beta signaling pathway as a therapeutic target in neurodegeneration. *Journal of Molecular Neuroscience*. 24: 149-153.
- 29 **Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C. & Husemann J. 2003.** Adult mouse astrocytes degrade amyloid-beta *in vitro* and *in situ*. *Nature Medicine*. 9: 453-457.
- 30 **Wyss-Coray T. & Mucke L. 2002.** Inflammation in neurodegenerative disease: A double-edged sword. *Neuron*. 35: 419-432.